Key Takeaways & Executive Findings
- •• Global patent filings for PD-1/PD-L1 inhibitors have grown exponentially, with China emerging as a major contributor. • Combination therapies and novel modalities (e.g., bispecific antibodies) are driving recent patent activity. • The United States and China lead in patent filings, but Europe shows significant activity in specific therapeutic areas. • Strategic patent management is crucial for navigating the competitive landscape of PD-1/PD-L1 inhibitors.
Abstract
This study provides a comprehensive analysis of global patent trends for PD-1/PD-L1 inhibitors, a class of immunotherapeutic agents that have revolutionized cancer treatment. By systematically examining patent filings from major jurisdictions including the United States, China, and Europe, we identify key trends in patent activity, technological focus, and geographic distribution. Our analysis reveals a significant surge in patent applications over the past decade, driven by the clinical success of PD-1/PD-L1 inhibitors and the expanding landscape of combination therapies. We also highlight the emergence of novel modalities such as bispecific antibodies and small molecule inhibitors, which are shaping the next generation of immunotherapies. The findings underscore the importance of strategic patent management in this highly competitive field and provide insights for researchers, clinicians, and policymakers. Our study contributes to the understanding of the innovation ecosystem surrounding PD-1/PD-L1 inhibitors and offers a roadmap for future research and development efforts.
1. Introduction
Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have transformed the treatment landscape for multiple malignancies. Since the approval of the first PD-1 inhibitor, pembrolizumab, in 2014, the field has witnessed rapid expansion, with numerous agents entering clinical development and the market. The success of these therapies has spurred intense research and development efforts, leading to a proliferation of patent filings worldwide. Understanding the patent landscape is essential for stakeholders to identify opportunities, avoid infringement, and inform strategic decisions.
This study presents a comprehensive analysis of global patent trends for PD-1/PD-L1 inhibitors, covering patent applications filed from 2000 to 2023. We examine the temporal evolution of patent filings, key players, technological domains, and geographic distribution. Our analysis also highlights emerging trends in combination therapies and novel drug modalities, providing a forward-looking perspective on the future of immunotherapy. By synthesizing patent data with clinical and commercial insights, we aim to offer a valuable resource for researchers, industry professionals, and policymakers.
Loading authentic research manuscript (Pages 1–5)...
ZHANG Wei, LI Ming, WANG Fang, CHEN Jie (2026). Global Trends in PD-1/PD-L1 Inhibitor Patents: A Comprehensive Analysis of Patent Landscapes and Therapeutic Innovations. Chinese Journal of New Drugs. https://doi.org/pub_80__articleID_418
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What are PD-1/PD-L1 inhibitors?
PD-1/PD-L1 inhibitors are a class of immunotherapeutic drugs that block the interaction between programmed cell death protein 1 (PD-1) on T cells and its ligand PD-L1 on tumor cells, thereby reactivating the immune system to attack cancer cells.
Why is patent analysis important for PD-1/PD-L1 inhibitors?
Patent analysis helps identify key players, technological trends, and potential areas for innovation, enabling strategic decisions in research, development, and commercialization.
Which countries lead in PD-1/PD-L1 inhibitor patents?
The United States and China are the leading countries in terms of patent filings, with significant contributions from Europe and other regions.
What are the emerging trends in PD-1/PD-L1 inhibitor patents?
Emerging trends include combination therapies with other agents, development of bispecific antibodies, and exploration of small molecule inhibitors.
How can this analysis benefit researchers and clinicians?
This analysis provides a comprehensive overview of the patent landscape, helping researchers identify potential collaborators, avoid patent infringement, and discover new avenues for drug development.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.